Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS.
OBJECTIVE
To investigate MRI and proton spectroscopy changes in five patients with HIV associated dementia complex (HADC) treated with antiretroviral therapy.


METHODS
Three markers were evaluated: (1) CSF/intracranial volume ratio; (2) T2 weighted signal ratio between parieto-occipital white and subcortical grey matter; and (3) metabolite ratios from long echo time (TE=135 ms) single voxel proton spectra of parieto-occipital white matter.


RESULTS
Spectroscopic changes indicated initial increases in N-acetyl/(N-acetyl + choline + creatine) ratio (NA/(NA+ Cho+Cr)) and progression of atrophy after initiation of antiretroviral therapy in four of five patients. When the neurological status of the patients subsequently deteriorated (two of five patients), the NA/(NA+Cho+Cr) ratio also declined.


CONCLUSIONS
Spectroscopic changes mirror reversible neuronal dysfunction. These objective, non-invasive techniques may be used for monitoring the neurological effects of antiretroviral drug therapy in patients with HADC.
Wilkinson
I D
ID
Department of Medical Physics and Bioengineering, The Middlesex Hospital, University College London Hospitals NHS Trust, UK.
Lunn
S
S
Miszkiel
K A
KA
Miller
R F
RF
Paley
M N
MN
Williams
I
I
Chinn
R J
RJ
Hall-Craggs
M A
MA
Newman
S P
SP
Kendall
B E
BE
Harrison
M J
MJ
D015526:AIDS Dementia Complex / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009778:Occipital Lobe / Q000473:pathology; D010296:Parietal Lobe / Q000473:pathology; D015215:Zidovudine / Q000627:therapeutic use*
D000998:Antiviral Agents; D015215:Zidovudine